{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:12:12Z","timestamp":1739164332511,"version":"3.37.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1097\/fpc.0b013e328328d507","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T22:51:15Z","timestamp":1242946275000},"page":"289-299","source":"Crossref","is-referenced-by-count":22,"title":["Deletion of the mouse Fmo1 gene results in enhanced pharmacological behavioural responses to imipramine"],"prefix":"10.1097","volume":"19","author":[{"given":"Diana","family":"Hernandez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azara","family":"Janmohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritpal","family":"Chandan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilal A.","family":"Omar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian R.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Shephard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210212","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.pharmthera.2005.01.001","article-title":"Mammalian flavin-containing monooxygenases: structure\/function, genetic polymorphisms and role in drug metabolism","volume":"106","author":"Krueger","year":"2005","journal-title":"Pharmacol Ther"},{"key":"R2-5-20210212","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.pharmtox.46.120604.141043","article-title":"Human flavin-containing monooxygenases","volume":"46","author":"Cashman","year":"2006","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R3-5-20210212","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2174\/157016007782793683","article-title":"The flavin-containing monooxygenases (FMOs): genetic variation and its consequences for the metabolism of therapeutic drugs","volume":"5","author":"Phillips","year":"2007","journal-title":"Curr Pharmacogenomics"},{"key":"R4-5-20210212","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.tips.2008.03.004","article-title":"Flavin-containing monooxygenases: mutations, disease and drug response","volume":"29","author":"Phillips","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"R5-5-20210212","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0026-895X(25)13662-6","article-title":"Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver","volume":"43","author":"Lemoine","year":"1993","journal-title":"Mol Pharmacol"},{"key":"R6-5-20210212","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/clpt.1991.77","article-title":"Role of P450IID6, the target of the sparteine-debrisoquine oxidation polymorphism, in the metabolism of imipramine","volume":"49","author":"Brosen","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"R7-5-20210212","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0090-9556(25)06778-9","article-title":"Effects of genetic or chemically induced diabetes on imipramine metabolism: respective involvement of flavin monooxygenase and cytochrome P-450-dependent monooxygenases","volume":"15","author":"Rouer","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"R8-5-20210212","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0090-9556(24)15176-8","article-title":"Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase 1","volume":"28","author":"Kim","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"R9-5-20210212","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/abbi.1997.0322","article-title":"Molecular cloning, sequencing, and expression in Escherichia coli of mouse flavin-containing monooxygenase 3 (FMO3): comparison with the human isoform","volume":"347","author":"Falls","year":"1997","journal-title":"Arch Biochem Biophys"},{"key":"R10-5-20210212","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/004982598239254","article-title":"Physiological factors affecting protein expression of flavin-containing monooxygenases 1, 3 and 5","volume":"28","author":"Cherrington","year":"1998","journal-title":"Xenobiotica"},{"key":"R11-5-20210212","first-page":"143","article-title":"Excessive plasma concentration of tricyclic antidepressants resulting from usual doses: a report of six cases","volume":"42","author":"Devane","year":"1981","journal-title":"J Clin Psychiatry"},{"key":"R12-5-20210212","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1176\/ajp.141.7.853","article-title":"Elevated plasma tricyclic levels with therapeutic doses of imipramine","volume":"141","author":"Garvey","year":"1984","journal-title":"Am J Psychiatry"},{"key":"R13-5-20210212","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1124\/dmd.31.2.187","article-title":"Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans","volume":"31","author":"Furnes","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R14-5-20210212","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/toxsci\/kfh079","article-title":"Evaluation of xenobiotic N- and S-oxidation by variant flavin-containing monooxygenase 1 (FMO1) enzymes","volume":"78","author":"Furnes","year":"2004","journal-title":"Toxicol Sci"},{"key":"R15-5-20210212","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/jpet.102.042911","article-title":"Human kidney flavin-containing monooxygenases and their potential roles in cysteine S-conjugate metabolism and nephrotoxicity","volume":"304","author":"Krause","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R16-5-20210212","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/14622416.6.8.807","article-title":"Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development","volume":"6","author":"Koukouritaki","year":"2005","journal-title":"Pharmacogenomics"},{"key":"R17-5-20210212","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1124\/jpet.103.053686","article-title":"Genetic variability at the human FMO1 locus: significance of a basal promoter yin yang 1 element polymorphism (FMO1*6)","volume":"306","author":"Hines","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R18-5-20210212","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00008571-200402000-00006","article-title":"Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters","volume":"14","author":"Hernandez","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R19-5-20210212","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1042\/BJ20070523","article-title":"Alternative promoters and repetitive DNA elements define the species-dependent tissue-specific expression of the FMO1 genes of human and mouse","volume":"406","author":"Shephard","year":"2007","journal-title":"Biochem J"},{"issue":"Suppl","key":"R20-5-20210212","first-page":"31S","article-title":"Buccal absorption of basic drugs and its application as an in vivo model of passive drug transfer through lipid membranes","volume":"19","author":"Beckett","year":"1967","journal-title":"J Pharm Pharmacol"},{"key":"R21-5-20210212","first-page":"37","article-title":"N-oxidation of drugs biochemistry, pharmacology, toxicology","author":"Midha","year":"1991"},{"key":"R22-5-20210212","first-page":"297","article-title":"Microsomes and drug oxidations","author":"Ziegler","year":"1988"},{"key":"R23-5-20210212","first-page":"307","article-title":"Cytochrome P450 protocols. 2nd ed","author":"Hernandez","year":"2006"},{"key":"R24-5-20210212","doi-asserted-by":"crossref","first-page":"14602","DOI":"10.1073\/pnas.94.26.14602","article-title":"Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells.","volume":"94","author":"O'Gorman","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R25-5-20210212","first-page":"321","article-title":"Cytochrome P450 protocols. 2nd ed","author":"Hernandez","year":"2006"},{"key":"R26-5-20210212","first-page":"329","article-title":"Cytochrome P450 protocols. 2nd ed","author":"Hernandez","year":"2006"},{"key":"R27-5-20210212","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0896-6273(00)80958-7","article-title":"Mutant mice and neuroscience: recommendations concerning genetic background. Banbury Conference on genetic background in mice","volume":"19","author":"Silva","year":"1997","journal-title":"Neuron"},{"key":"R28-5-20210212","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00335-002-2188-1","article-title":"Novel phenotypes identified by plasma biochemical screening in the mouse","volume":"13","author":"Hough","year":"2002","journal-title":"Mamm Genome"},{"key":"R29-5-20210212","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s003359900551","article-title":"Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment","volume":"8","author":"Rogers","year":"1997","journal-title":"Mamm Genome"},{"key":"R30-5-20210212","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/abio.2001.5530","article-title":"A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics","volume":"302","author":"Liu","year":"2002","journal-title":"Anal Biochem"},{"key":"R31-5-20210212","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1042\/bj1960839","article-title":"Induction by phenobarbital of the mRNA for a specific variant of rat liver microsomal cytochrome P-450","volume":"196","author":"Phillips","year":"1981","journal-title":"Biochem J"},{"key":"R32-5-20210212","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng1297-491","article-title":"Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome","volume":"17","author":"Dolphin","year":"1997","journal-title":"Nat Genet"},{"key":"R34-5-20210212","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/0378-4347(95)00084-V","article-title":"Rapid microsample analysis of imipramine and desipramine by reversed-phase high-performance liquid chromatography with ultraviolet detection.","volume":"668","author":"Yoo","year":"1995","journal-title":"J Chromatogr B Biomed Appl"},{"key":"R35-5-20210212","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/026988110001400403","article-title":"Clozapine pharmacokinetics and pharmacodynamics studied with Cyp1A2-null mice","volume":"14","author":"Aitchison","year":"2000","journal-title":"J Psychopharmacol"},{"key":"R36-5-20210212","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1600-0773.1978.tb02170.x","article-title":"The kinetics of imipramine N-oxide in rats","volume":"42","author":"Nagy","year":"1978","journal-title":"Acta Pharmacol Toxicol"},{"key":"R37-5-20210212","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.2042-7158.1973.tb10644.x","article-title":"Quantitative determination of imipramine and desipramine in human blood plasma by direct densitometry of thin-layer chromatograms","volume":"25","author":"Nagy","year":"1973","journal-title":"J Pharm Pharmacol"},{"key":"R38-5-20210212","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-0773.1978.tb02169.x","article-title":"The kinetics of imipramine N-oxide in man","volume":"42","author":"Nagy","year":"1978","journal-title":"Acta Pharmacol Toxicol"},{"key":"R39-5-20210212","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1093\/nar\/27.11.2354","article-title":"A system for rapid generation of coat color-tagged knockouts and defined chromosomal rearrangements in mice","volume":"27","author":"Zheng","year":"1999","journal-title":"Nucleic Acids Res"},{"key":"R40-5-20210212","doi-asserted-by":"crossref","first-page":"12379","DOI":"10.1016\/S0021-9258(18)98908-8","article-title":"Cloning, primary sequence, and chromosomal mapping of a human flavin-containing monooxygenase (FMO1)","volume":"266","author":"Dolphin","year":"1991","journal-title":"J Biol Chem"},{"key":"R41-5-20210212","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0009-2797(94)03580-2","article-title":"The molecular biology of the flavin-containing monooxygenases of man","volume":"96","author":"Phillips","year":"1995","journal-title":"Chem Biol Interact"},{"key":"R42-5-20210212","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1203\/00006450-200202000-00018","article-title":"Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression","volume":"51","author":"Koukouritaki","year":"2002","journal-title":"Pediatr Res"},{"key":"R43-5-20210212","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0090-9556(24)15194-X","article-title":"Immunoquantitation of FMO1 in human liver, kidney, and intestine","volume":"28","author":"Yeung","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"R44-5-20210212","doi-asserted-by":"crossref","first-page":"30599","DOI":"10.1074\/jbc.273.46.30599","article-title":"The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein","volume":"273","author":"Dolphin","year":"1998","journal-title":"J Biol Chem"},{"key":"R45-5-20210212","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1006\/taap.2000.9050","article-title":"Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans","volume":"168","author":"Whetstine","year":"2000","journal-title":"Toxicol Appl Pharmacol"},{"key":"R46-5-20210212","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/FPC.0b013e3283097311","article-title":"The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa","volume":"18","author":"Veeramah","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R47-5-20210212","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bcp.2004.02.036","article-title":"Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenases (Fmos)","volume":"68","author":"Janmohamed","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"R48-5-20210212","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0003-9861(90)90729-I","article-title":"Evidence for the presence of distinct flavin-containing monooxygenases in human tissues","volume":"276","author":"Lemoine","year":"1990","journal-title":"Arch Biochem Biophys"},{"key":"R49-5-20210212","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/archpsyc.1984.01790120059008","article-title":"Subjective complaints during desipramine treatment. Relative importance of plasma drug concentrations and the severity of depression","volume":"41","author":"Nelson","year":"1984","journal-title":"Arch Gen Psychiatry"},{"key":"R50-5-20210212","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1600-0447.1973.tb04400.x","article-title":"Comparative trial of imipramine N-oxide and imipramine in the treatment of out-patients with depressive syndromes","volume":"49","author":"Rapp","year":"1973","journal-title":"Acta Psychiatr Scand"},{"key":"R51-5-20210212","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1432-1033.1996.00683.x","article-title":"Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FM04","volume":"235","author":"Dolphin","year":"1996","journal-title":"Eur J Biochem"},{"key":"R52-5-20210212","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.2042-7158.1973.tb10645.x","article-title":"Imipramine and its metabolites in human brain","volume":"25","author":"Christiansen","year":"1973","journal-title":"J Pharm Pharmacol"},{"key":"R53-5-20210212","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/00007691-199306000-00009","article-title":"Simultaneous high-performance liquid chromatography-electrochemical detection determination of imipramine, desipramine, their 2-hydroxylated metabolites, and imipramine N-oxide in human plasma and urine: preliminary application to oxidation pharmacogenetics","volume":"15","author":"Koyama","year":"1993","journal-title":"Ther Drug Monit"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/01213011-200904000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T16:50:32Z","timestamp":1739119832000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-200904000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e328328d507","relation":{},"ISSN":["1744-6872"],"issn-type":[{"type":"print","value":"1744-6872"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}